Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc., (Nasdaq: KITE), a leading cell therapy company, today announced that patients in the European Union (EU) are now being...